CGTX · Cognition Therapeutics Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $6.12M | - | $3.77M | $11.48M | $10.79M | - | $11.39M | $11.58M | $10.55M | - |
| SG&A | $2.70M | - | $2.60M | $2.50M | $2.99M | - | $3.07M | $3.10M | $3.55M | - |
| Total Operating Expenses | $8.82M | - | $6.38M | $13.98M | $13.78M | - | $14.46M | $14.68M | $14.10M | - |
| D&A | - | - | - | - | - | - | - | - | $27.0K | - |
| Operating Income | ($8.82M) | - | ($6.38M) | ($13.98M) | ($13.78M) | - | ($14.46M) | ($14.68M) | ($14.10M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($4.57M) | - | ($4.93M) | ($6.73M) | ($8.48M) | - | ($9.94M) | ($7.04M) | ($9.15M) | - |
| EPS - Basic | ($0.05) | - | ($0.06) | ($0.11) | ($0.14) | - | ($0.25) | ($0.18) | ($0.27) | - |
| EPS - Diluted | ($0.05) | - | ($0.06) | ($0.11) | ($0.14) | - | ($0.25) | ($0.18) | ($0.27) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $31.13M | $36.81M | $39.33M | $10.74M | $16.43M | $25.01M | $22.01M | $28.53M | $34.67M | $29.92M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.85M | $1.12M | $827.0K | $771.0K | $1.82M | $1.98M | $1.90M | $3.03M | $2.64M | $3.69M |
| Current Assets | $35.81M | $47.99M | $42.88M | $19.05M | $22.87M | $29.55M | $26.83M | $33.55M | $37.97M | $34.22M |
| Total Assets | $36.14M | $48.39M | $43.40M | $19.62M | $23.50M | $30.23M | $27.58M | $34.37M | $38.85M | $35.16M |
| Current Liabilities | $6.05M | $13.92M | $6.65M | $12.36M | $10.95M | $11.14M | $12.71M | $10.92M | $9.50M | $10.17M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $6.23M | $14.12M | $6.87M | $12.59M | $11.23M | $11.48M | $13.10M | $11.36M | $9.99M | $10.69M |
| Stockholders' Equity | $29.91M | $34.27M | $36.53M | $7.03M | $12.27M | $18.75M | $14.48M | $23.01M | $28.86M | $24.47M |
| Retained Earnings | ($203.22M) | ($198.65M) | ($195.30M) | ($190.37M) | ($183.64M) | ($175.16M) | ($167.32M) | ($157.38M) | ($150.34M) | ($141.19M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.54M) | - | - | - | ($9.88M) | - | - | - | ($7.24M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | ($233.0K) | - | - | - | $1.30M | - | - | - | $11.99M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.6% | - | -11.4% | -34.3% | -36.1% | - | -36.0% | -20.5% | -23.6% | - |
| Return on equity | -15.3% | - | -13.5% | -95.8% | -69.1% | - | -68.6% | -30.6% | -31.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.92 | 3.45 | 6.44 | 1.54 | 2.09 | 2.65 | 2.11 | 3.07 | 4.00 | 3.37 |
| Quick ratio | 5.92 | 3.45 | 6.44 | 1.54 | 2.09 | 2.65 | 2.11 | 3.07 | 4.00 | 3.37 |
| Cash ratio | 5.14 | 2.64 | 5.91 | 0.87 | 1.50 | 2.24 | 1.73 | 2.61 | 3.65 | 2.94 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.21 | 1.41 | 1.19 | 2.79 | 1.92 | 1.61 | 1.90 | 1.49 | 1.35 | 1.44 |
| Liabilities / Assets | 0.17 | 0.29 | 0.16 | 0.64 | 0.48 | 0.38 | 0.47 | 0.33 | 0.26 | 0.30 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.3x | - | 2.9x | 2.8x | 2.1x | - | 1.3x | 2.9x | 2.1x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 36.0% | - | 55.9% | 4.8% | 2.3% | - | 1.9% | -24.2% | -57.2% | - |
| Net income growth (YoY) | 46.1% | - | 50.4% | 4.4% | 7.3% | - | -47.2% | -49.0% | -48.3% | - |
| EPS growth (YoY) | 64.3% | - | 76.0% | 38.9% | 48.1% | - | -13.6% | -12.5% | -28.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 143.8% | 82.8% | 152.2% | -69.5% | -57.5% | -23.4% | -49.9% | -33.1% | -19.3% | -39.2% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing COGNITION THERAPEUTICS INC against the 5 most active filers in the same SIC group.